Physician profile
Tanci Burrow
NPI 1851482921
$4,243.02
in general payments reported to CMS, 2019-2025
16 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $1,483 · 2023: $771 · 2024: $998 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $750.77 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $644.32 | 2022-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $476.12 | 2021-2024 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $432.55 | 2021-2025 | Caplyta |
| Indivior INC. | $429.32 | 2022-2024 | Perseris |
| Abbvie INC. | $372.92 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $270.69 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $253.56 | 2021-2024 | Aristada, Lybalvi |
| Lilly USA, LLC | $172.27 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Vanda Pharmaceuticals INC. | $157.92 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $100.06 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.94 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.19 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $38.35 | 2023-2025 | Qelbree, Qelbree |
| Eisai INC. | $20.43 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $13.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanci Burrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.